MAP2K7 and melanoma: In order to delay the onset of resistance, the concomitant administration of BRAFi with MEK inhibitors (MEKi), binimetinib, trametinib or cobimetinib, is currently standard care for advanced BRAFV600-mutated (BRAFmut) melanoma and has also reduced secondary skin malignancies [26,27,28,29,30,31].